Table 4.
Excess Economic Burden Estimates of Antimicrobial Resistance
| Study | Exposure Group | Control Group | Country | Method | Excess Cost Estimate (2013 USD) |
|---|---|---|---|---|---|
| Cost per case | |||||
| [135] | MDR TB | Susceptible TB | Germany | Stepwise Calculation | 110,063 |
| [135] | XDR TB | Susceptible TB | Germany | Stepwise Calculation | 145,679 |
| [143] | MDR TB | Susceptible TB | Europe | Stepwise Calculation | 62,931 |
| [143]) | XDR TB | Susceptible TB | Europe | Stepwise Calculation | 215,038 |
| [56] | MRSA BSI | Non-nosocomial-infected patients | South Korea | Matching | 21,832 |
| Annual cost per stated country or stated region | |||||
| [141] | Resistant Streptococcus pneumonia | Susceptible Streptococcus pneumonia | USA | Multistate model | 236,495,000 |
| [57] | MRSA | No MRSA | USA | Multistate model | 7,848,223,600 |
| [142] | Artemisinin resistant malaria | No resistance | High endemicity regions | Decision Tree | 385,000,000 |
| Global economic cost | |||||
| [15] | Resistance globally (doubling of current infection rates and 100% resistance) | Lower rates of resistance (a 40% resistance increase from current rates) | Global | Total Factor Productivity model | 14,228,000,000 less GDP produced in 2050 compared to 2050 in a scenario with lower resistance |
| [55] | Resistance globally (100% resistance rate) | No resistance | Global | Computable General Equilibrium model | 3,158,862,360 less GDP produced in 2050 compared to 2050 with no resistance |